Abliva Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Abliva şirketinin toplam hissedar öz sermayesi SEK67.4M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK75.7M ve SEK8.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 45.25m
Eşitlik	SEK 67.42m
Toplam yükümlülükler	SEK 8.28m
Toplam varlıklar	SEK 75.70m

Son finansal sağlık güncellemeleri

Recent updates

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Oct 02

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Dec 18

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Aug 24

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Aug 21

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Oct 13

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Mar 22

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Dec 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ABLI 'nin kısa vadeli varlıkları ( SEK50.9M ) kısa vadeli yükümlülüklerini ( SEK8.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: ABLI şirketinin kısa vadeli varlıkları ( SEK50.9M ) uzun vadeli yükümlülüklerini ( SEK216.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ABLI borçsuzdur.

Borcun Azaltılması: ABLI son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ABLI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ABLI un, serbest nakit akışı her yıl % 2.9 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Abliva Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Recent updates

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

New major risk - Shareholder dilution

New major risk - Financial position

Abliva AB (publ) Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin